Sugi Predict

Sugi Predict / Compounds / SCHEMBL2679655

SCHEMBL2679655

SCHEMBL2679655

CCCC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3[C@@H](O)C[C@@]21C

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 11/20 0.88
▸ SMN1; SMN2 Q16637 3/20 0.88
▸ MAPT P10636 2/20 0.88
▸ POLB P06746 1/20 0.88
▸ GAA P10253 1/20 0.88
▸ NFKB1 P19838 2/20 0.83
▸ PMP22 Q01453 1/20 0.83
▸ TSHR P16473 1/20 0.83
▸ PGR P06401 4/20 0.81
▸ SERPINA6 P08185 2/20 0.81
▸ LMNA P02545 2/20 0.81
▸ AR P10275 2/20 0.81
▸ CHRM1 P11229 2/20 0.81
▸ CYP3A4 P08684 2/20 0.79
▸ NR3C2 P08235 4/20 0.73
▸ NR3C1 P04150 3/20 0.73
▸ CYP2C19 P33261 2/20 0.73
▸ HSD17B10 Q99714 2/20 0.73
▸ KMT2A Q03164 2/20 0.73
▸ SHBG P04278 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11252568 1.00 HIF1A (0.88) HIF1ASMN1; SMN2MAPTPOLBGAA
SCHEMBL4696 1.00 HIF1A (0.88) HIF1ASMN1; SMN2MAPTPOLBGAA
SCHEMBL10575587 1.00 HIF1A (0.88) HIF1ASMN1; SMN2MAPTPOLBGAA
Hydrocortisone SCHEMBL365193 0.97 HIF1A (0.83) HIF1ASMN1; SMN2MAPTPOLBGAA
Hydrocortisone Acetate SCHEMBL1535103 0.97 HIF1A (0.87) HIF1ASMN1; SMN2MAPTPOLBGAA
SCHEMBL80604 0.96 HIF1A (0.95) HIF1ASMN1; SMN2MAPTPOLBGAA
SCHEMBL2679288 0.96 HIF1A (0.95) HIF1ASMN1; SMN2MAPTPOLBGAA
SCHEMBL16018308 0.96 HIF1A (0.93) HIF1ASMN1; SMN2MAPTPOLBGAA
SCHEMBL5084679 0.94 HIF1A (0.98) HIF1ASMN1; SMN2MAPTPOLBGAA
SCHEMBL7137200 0.94 HIF1A (1.00) HIF1ASMN1; SMN2MAPTPOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 755 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352645-B2 Compositions and methods for treating Leber's hereditary optic neuropathy Wuhan Neurophth Biotechnology Limited Company (CN) 2022-06-07 — — US claimed
EP-3840785-A1 COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY Wuhan Neurophth Biotechnology Limited Company (CN) 2021-06-30 — — EP claimed
US-20210189429-A1 COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY Wuhan Neurophth Biotechnology Limited Company (CN) 2021-06-24 — — US claimed
WO-2020038352-A1 COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY WUHAN NEUROPHTH BIOLOGICAL TECHNOLOGY LIMITED COMPANY (CN) 2020-02-27 — — WO claimed
US-7745138-B2 Methods for determining drug responsiveness THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2010-06-29 — — US claimed
US-20100152100-A1 ACCELERATED THERAPY GLOUCESTER PHARMACEUTICALS, INC. 2010-06-17 — — US claimed
WO-2010047714-A1 CANCER THERAPY GLOUCESTER PHARMACEUTICALS (US) 2010-04-29 — — WO claimed
WO-2010014819-A1 ACCELERATED THERAPY GLOUCESTER PHARMACEUTICALS, INC. (US) 2010-02-04 — — WO claimed
US-20090286248-A1 Methods for Determining Drug Responsiveness THE TRUSTEES OF THE UNIVERSITY OF PENSYLVANIA 2009-11-19 — — US claimed
EP-2117556-A2 COMBINATION THERAPY COMPRISING ROMIDEPSIN AND I.A. BORTEZOMIB Gloucester Pharmaceuticals, Inc. (US) 2009-11-18 — — EP claimed
US-20090105200-A1 Combination therapy GLOUCESTER PHARMACEUTICALS 2009-04-23 — — US claimed
WO-2008091620-A2 COMBINATION THERAPY COMPRISING ROMIDEPSIN AND I.A. BORTEZOMIB GLOUCESTER PHARMACEUTICALS, INC. (US) 2008-07-31 — — WO claimed
US-6878518-B2 Methods for determining steroid responsiveness THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2005-04-12 — — US claimed
US-20040203031-A1 Methods for determining drug responsiveness UNIVERSITY OF PENNSYLVANIA 2004-10-14 — — US claimed
WO-2003062792-A2 METHODS FOR DETERMINING DRUG RESPONSIVENESS TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2003-07-31 — — WO claimed
US-20030138781-A1 Methods for determining steroid responsiveness UNIVERSITY OF PENNSYLVANIA 2003-07-24 — — US claimed
US-11352645-B2 Compositions and methods for treating Leber's hereditary optic neuropathy Wuhan Neurophth Biotechnology Limited Company (CN) 2022-06-07 — — US disclosed
EP-3840785-A1 COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY Wuhan Neurophth Biotechnology Limited Company (CN) 2021-06-30 — — EP disclosed
WO-2001046254-A1 TRANSFERRIN POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES HUMAN GENOME SCIENCES, INC. (US) 2001-06-28 — — WO disclosed
WO-2001046475-A1 TREFOIL DOMAIN-CONTAINING POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES HUMAN GENOME SCIENCES, INC. (US) 2001-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105200-A1 Combination therapy MCL1, BCL3, PSMB5 HIF1A 3574/4885SMN1; SMN2 2358/4885MAPT 4375/4885
US-20100152100-A1 ACCELERATED THERAPY LPXN, PSAP, ERAP1 HIF1A 1621/4885SMN1; SMN2 259/4885MAPT 3714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.